What is MGC Pharmaceuticals Limited (MGCLF)?

MGC Pharmaceuticals Limited (MGCLF) is a stock in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. View full analysis on Stocks360.

What is the current price of MGCLF?

The current price of MGCLF is $0.27. Prices are updated in real time on Stocks360.

What is MGCLF's price-to-earnings (PE) ratio?

MGCLF's trailing twelve-month PE ratio is -0.05, based on current price and earnings per share data available on Stocks360.

What is MGCLF's market capitalization?

MGCLF's market capitalization is $12,112,454.00, placing it in the small-cap tier.

MGC Pharmaceuticals Limited (MGCLF)

Stock analysis · OTC · Healthcare · Drug Manufacturers - Specialty & Generic

$0.27

Market Cap

$12.11M

PE (TTM)

-0.05

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.97

Day Range

$0.27 – $0.27

52-wk Range

$0.23 – $5.10

Avg Volume

N/A

Volume

1.02K

MGC Pharmaceuticals Limited (MGCLF) is a publicly traded company in the Healthcare sector. Latest price: $0.27. Market cap $12.11M. Trailing PE -0.05. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Proprietary Signals

Signal snapshot temporarily unavailable.

About MGC Pharmaceuticals Limited

MGC Pharmaceuticals Limited is a biopharmaceutical company dedicated to the global development and provision of plant-derived medicines. The firm manufactures and distributes both medical cannabis products and a range of non-cannabis botanical therapeutics. Among its key investigational drug candidates are CimetrA, which is undergoing Phase III clinical trials for the symptomatic treatment of early-stage COVID-19; CannEpil, a Phase IIb cannabis-based therapy targeting drug-resistant epilepsy; and CogniCann, currently in Phase II clinical evaluation for the symptomatic relief of dementia. Beyond its core pipeline, MGC Pharmaceuticals also offers its ArtemiC product line, various cannabinoid-focused items, and other non-pharmaceutical goods. The company further extends its services to include consulting, particularly in clinical research. Established in 2014 and headquartered in West Perth, Australia, the company previously operated as Erin Resources Limited before rebranding to MGC Pharmaceuticals Limited in December 2015.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.05×
P/S (TTM)	5.08×
P/B	-0.15×
P/FCF (TTM)	-1.41×
EV / EBITDA	-1.31×
EV / Sales	7.89×
Earnings Yield	-1859.47%
Free Cash Flow Yield	-70.76%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$26.72M
Revenue (TTM)	$3.39M
Net Income (TTM)	-$319.96M
Free Cash Flow (TTM)	-$11.92M
Net Debt	$9.51M
Working Capital	-$10.80M
Gross Margin	37.96%
Operating Margin	-457.29%
Net Margin	-614.64%
Return on Equity	2660.08%
Return on Invested Capital	-257.29%